These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17584041)

  • 1. Metabolic syndrome in an Asian Chinese population and agents and targets for cardiovascular protection.
    Fung ML; Wong TM
    Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):77-8. PubMed ID: 17584041
    [No Abstract]   [Full Text] [Related]  

  • 2. Searching for phytoinsulins as cardiovascular protector in metabolic syndrome.
    Ji L; Xing W; Dong L; Gao F
    Curr Pharm Des; 2013; 19(27):4848-58. PubMed ID: 23323618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Managing the cardiovascular risk associated with the metabolic syndrome.
    Montalto G; Rizzo M; Mikhailidis DP
    Curr Pharm Des; 2014; 20(31):4941-3. PubMed ID: 24320029
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
    Basile J; Houston M; Ferrario CM
    J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic syndrome and cardiovascular disease in elderly people in rural China: a population-based study.
    Liang Y; Yan Z; Song A; Cai C; Sun B; Jiang H; Qiu C
    J Am Geriatr Soc; 2013 Jun; 61(6):1036-1038. PubMed ID: 23772734
    [No Abstract]   [Full Text] [Related]  

  • 6. Point: the metabolic syndrome still lives.
    Grundy SM
    Clin Chem; 2005 Aug; 51(8):1352-4. PubMed ID: 16040840
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of metabolic syndrome among middle-aged and elderly adults in China: current status and temporal trends.
    Li W; Song F; Wang X; Wang L; Wang D; Yin X; Cao S; Gong Y; Yue W; Yan F; Zhang H; Sheng Z; Wang Z; Lu Z
    Ann Med; 2018 Jun; 50(4):345-353. PubMed ID: 29637787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
    Greenberg AS
    J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperleptinemia, hyperinsulinemia and metabolic syndrome in cardiovascular risk: one for all and all for one].
    Botella Carretero JI
    Med Clin (Barc); 2004 Dec; 123(20):780-1. PubMed ID: 15607071
    [No Abstract]   [Full Text] [Related]  

  • 10. [The metabolic syndrome and inflammation: actual issues of pathogenesis].
    Sveklina TS; Talantseva MS; Barsukov AV
    Klin Lab Diagn; 2013 Mar; (3):7-10. PubMed ID: 23808015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of home blood pressure and ambulatory blood pressure monitoring in decisions of when and whom to treat: recommendations for practicing clinicians.
    Ogedegbe G
    J Cardiometab Syndr; 2006; 1(3):222-4. PubMed ID: 17679827
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum Alanine Aminotransferase Is Associated with Metabolic Syndrome and 10-year Risk of Cardiovascular Disease.
    Ma LN; DU R; Cheng D; Lin L; Wu XY; Hu CY; Dai M; Xu Y; Xu M; Jiang L; Li M; Lu JL; Bi YF; Wang WQ; Ning G
    Biomed Environ Sci; 2019 Feb; 32(2):121-125. PubMed ID: 30862343
    [No Abstract]   [Full Text] [Related]  

  • 13. Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):146-8. PubMed ID: 17679828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiovascular risk in subjects with high probability of metabolic syndrome and insulin resistance. DESIRE study].
    Goday A; Gabriel R; Ascaso JF; Franch J; Ortega R; Martínez O; Lerones N;
    Rev Clin Esp; 2008 Sep; 208(8):377-85. PubMed ID: 18817695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardiovascular continuum in Asia--a new paradigm for the metabolic syndrome.
    Cheung BM
    J Cardiovasc Pharmacol; 2005 Aug; 46(2):125-9. PubMed ID: 16044022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk protection. Call to action.
    Cohn PE
    Am J Manag Care; 2002 Jun; 8(9 Suppl):40. PubMed ID: 12099328
    [No Abstract]   [Full Text] [Related]  

  • 17. Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
    Zimmet P
    Trends Cardiovasc Med; 2002 Nov; 12(8):354-62. PubMed ID: 12536122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cardiovascular risk factor case management on the metabolic syndrome in a primary prevention population: results from a randomized controlled trial.
    O'Malley PG; Kowalczyk C; Bindeman J; Taylor AJ
    J Cardiometab Syndr; 2006; 1(1):6-12. PubMed ID: 17675895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome and cardiovascular risk.
    Hu G; Qiao Q; Tuomilehto J
    Curr Diabetes Rev; 2005 May; 1(2):137-43. PubMed ID: 18220589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison Between Metabolic Syndrome and the Framingham Risk Score as Predictors of Cardiovascular Diseases Among Kazakhs in Xinjiang.
    Yang W; Ma R; Zhang X; Guo H; He J; Mao L; Mu L; Hu Y; Yan Y; Liu J; Ma J; Li S; Ding Y; Zhang M; Zhang J; Guo S
    Sci Rep; 2018 Nov; 8(1):16474. PubMed ID: 30405180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.